MorphoSys AG

As of December 31, 2023, MorphoSys AG has 37.60M shares outstanding.

As of December 31, 2023, MorphoSys AG trades at a trailing price-to-earnings ratio of 15.08. The price-to-sales ratio is 5.14, and the price-to-book ratio stands at -1.26.

These figures are as of December 31, 2023. The EV/Sales ratio of 4.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of December 31, 2023, MorphoSys AG maintains a current ratio of 3.08, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1,296.52, indicating moderate leverage, while an interest coverage ratio of -1.85 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2023. Return on assets (ROA) is negative at -8.58, reflecting losses generated across the asset base. Inventory turnover of 1.35 indicates how many times MorphoSys AG sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2023, MorphoSys AG posted a gross margin of 75.52, reflecting its pricing power and cost economics. The operating margin of -105.22 and net profit margin of -79.60 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2023. Free cash flow yield is negative at -16.04: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 4.08, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to MorphoSys AG shareholders.

As of December 31, 2023, MorphoSys AG has an Altman Z-Score of -1.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.